ESR1 and metastatic neoplasm: In this regard, the indirect effect of statin treatment which results in decreasing the systemic levels of total cholesterol, LDL-cholesterol and by inference 27-hydroxycholesterol may thus inhibit tumor proliferation and prevent or delay the onset of metastatic disease [7], providing a molecular basis for the benefits of using statins to control ER positive breast cancers.